Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.30% | -30.66% | -33.83% | -21.66% | 61.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.30% | -30.66% | -33.83% | -21.66% | 61.95% |
| Cost of Revenue | -11.20% | -13.89% | -13.82% | -13.60% | -12.75% |
| Gross Profit | 0.25% | 5.92% | 4.78% | 10.37% | 30.27% |
| SG&A Expenses | -9.68% | -11.30% | -12.40% | -12.60% | -7.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.84% | -13.29% | -13.50% | -13.38% | -11.60% |
| Operating Income | 3.26% | 7.57% | 7.06% | 11.02% | 24.34% |
| Income Before Tax | 9.95% | 9.91% | 8.05% | 11.62% | 25.99% |
| Income Tax Expenses | -- | -- | -- | -11.34% | 81.36% |
| Earnings from Continuing Operations | 12.78% | 13.46% | 11.99% | 11.61% | 24.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.78% | 13.46% | 11.99% | 11.61% | 24.59% |
| EBIT | 3.26% | 7.57% | 7.06% | 11.02% | 24.34% |
| EBITDA | 3.20% | 7.51% | 6.98% | 11.15% | 24.95% |
| EPS Basic | 38.37% | 38.33% | 29.65% | 22.51% | 29.03% |
| Normalized Basic EPS | 34.64% | 37.99% | 28.57% | 24.67% | 32.18% |
| EPS Diluted | 38.37% | 38.33% | 29.65% | 22.51% | 29.03% |
| Normalized Diluted EPS | 34.64% | 37.99% | 28.57% | 24.67% | 32.18% |
| Average Basic Shares Outstanding | 40.97% | 42.36% | 30.73% | 18.74% | 6.67% |
| Average Diluted Shares Outstanding | 40.97% | 42.36% | 30.73% | 18.74% | 6.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |